SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-008235
Filing Date
2022-05-09
Accepted
2022-05-09 07:11:01
Documents
76
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q fulc-20220331.htm   iXBRL 10-Q 2750118
2 EX-31.1 fulc-ex31_1.htm EX-31.1 15841
3 EX-31.2 fulc-ex31_2.htm EX-31.2 19334
4 EX-32.1 fulc-ex32_1.htm EX-32.1 8713
5 EX-32.2 fulc-ex32_2.htm EX-32.2 8844
  Complete submission text file 0000950170-22-008235.txt   9803577

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT fulc-20220331_def.xml EX-101.DEF 250451
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fulc-20220331.xsd EX-101.SCH 59361
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fulc-20220331_lab.xml EX-101.LAB 460273
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fulc-20220331_pre.xml EX-101.PRE 371594
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT fulc-20220331_cal.xml EX-101.CAL 48583
70 EXTRACTED XBRL INSTANCE DOCUMENT fulc-20220331_htm.xml XML 1932993
Mailing Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139
Business Address 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 617-651-8851
Fulcrum Therapeutics, Inc. (Filer) CIK: 0001680581 (see all company filings)

IRS No.: 474839948 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38978 | Film No.: 22903227
SIC: 2834 Pharmaceutical Preparations